Ironwood Pharmaceuticals, Inc. focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation.
Market Cap | 1.529 Billion | Shares Outstanding | 159.22 Million | Avg 30-day Volume | 2.066 Million |
P/E Ratio | 12.3144 | Dividend Yield | 0.0 | EPS | 0.33 |
Price to Revenue | 5.1286 | Debt to Equity | 0.0 | EBITDA | 249.581 Million |
Price to Book Value | 0.0 | Operating Margin | 56.6032 | Enterprise Value | 0 |
Current Ratio | 0 | EPS Growth | -0.685 | Quick Ratio | 0 |
1 Yr BETA | 0.6786 | 52-week High/Low | 12.66 / 8.08 | Profit Margin | 41.6469 |
Operating Cash Flow Growth | 16.5848 | Free Cash Flow to Firm (FCFF) TTM | 647.713 Million | Free Cash Flow to Equity (FCFE) TTM | 308.721 Million |
Altman Z-Score | 0.0 | ||||
Earnings Report | 2024-02-22 |
Please sign in first
none
3.3 Thousand total shares from 1 transactions
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
DAVIS ANDREW SVP, CHIEF BUSINESS OFFICER |
|
217,374 | 2023-11-20 | 4 |
EMANY SRAVAN KUMAR SVP, CHIEF FINANCIAL OFFICER |
|
182,069 | 2023-11-16 | 3 |
|
16,508,930 | 2023-09-15 | 5 | |
|
127,061 | 2023-09-15 | 4 | |
SILVER RONALD PRINCIPAL ACCOUNTING OFFICER |
|
142,172 | 2023-08-29 | 4 |
JOHN MINARDO CHIEF LEGAL OFFICER |
|
192,195 | 2023-08-14 | 3 |
|
544,108 | 2023-06-20 | 1 | |
|
162,294 | 2023-06-20 | 1 | |
|
102,244 | 2023-06-20 | 1 | |
|
168,980 | 2023-06-20 | 1 | |
|
106,498 | 2023-06-20 | 1 | |
|
114,108 | 2023-06-20 | 1 | |
MCCOURT THOMAS A CHIEF EXECUTIVE OFFICER |
|
758,284 | 2023-05-30 | 9 |
SHETZLINE MICHAEL CMO,SVP,HEAD-RES&DRUG |
|
321,131 | 2023-05-22 | 4 |
RICKARD JASON SVP, CHIEF OPERATING OFFICER |
|
376,316 | 2023-03-08 | 4 |
|
91,395 | 2021-06-02 | 0 | |
|
281,720 | 2021-06-02 | 0 | |
CONSYLMAN GINA SVP, CFO & TREASURER |
|
392,616 | 2021-03-26 | 0 |
|
29,972,944 | 2021-02-26 | 5 | |
MALLON MARK CHIEF EXECUTIVE OFFICER |
|
470,605 | 2021-02-26 | 0 |
KILROY CONOR SVP, GC & SECRETARY |
|
No longer subject to file | 2021-02-26 | 0 |
MACDONALD KELLY CHIEF ACCOUNTING OFFICER |
|
93,041 | 2020-12-04 | 0 |
GILBERT HALLEY E CHIEF ADMIN OFFICER & SVP |
|
265,991 | 2020-02-21 | 0 |
|
No longer subject to file | 2019-04-01 | 0 | |
|
No longer subject to file | 2019-04-01 | 0 | |
|
No longer subject to file | 2019-04-01 | 0 | |
|
No longer subject to file | 2019-04-01 | 0 | |
HECHT PETER M CHIEF EXECUTIVE OFFICER |
|
No longer subject to file | 2019-04-01 | 0 |
HUYETT WILLIAM CHIEF OPERATING OFFICER |
|
No longer subject to file | 2019-04-01 | 0 |
|
374,525 | 2017-03-15 | 0 | |
GRANEY THOMAS CHIEF FINANCIAL OFFICER |
|
42,013 | 2017-02-27 | 0 |
|
123,978 | 2015-06-15 | 0 | |
|
635,976 | 2015-06-03 | 0 | |
|
101,233 | 2015-03-13 | 0 | |
|
328,080 | 2015-03-11 | 0 | |
HIGGINS MICHAEL J CHIEF OPERATING OFFICER |
|
329,102 | 2014-12-23 | 0 |
|
393,455 | 2014-03-14 | 0 | |
|
837,736 | 2013-03-28 | 0 | |
|
No longer subject to file | 2013-03-15 | 0 | |
VHCP CO-INVESTMENT HOLDINGS, LLC VENROCK HEALTHCARE CAPITAL PARTNERS LP |
|
No longer subject to file | 2013-03-15 | 0 |
|
2,340,891 | 2012-07-09 | 0 | |
RIDGEBACK CAPITAL INVESTMENTS L.P. |
|
No longer subject to file | 2012-02-02 | 0 |
|
42,667 | 2011-03-31 | 0 | |
VENROCK MANAGEMENT LLC VENROCK HEALTHCARE CAPITAL PARTNERS LP |
|
8,731,321 | 2010-02-02 | 0 |
|
770,952 | 2010-02-02 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2023-11-22 16:05:22 -0500 | 2023-11-20 | S | 3,287 | $9.69 | d | 217,374 | direct | -0.1041 | 0.0 | 1 | -0.1041 | 2 | ||||
2023-11-20 16:05:22 -0500 | 2023-11-16 | F | 6,661 | $9.44 | d | 182,069 | direct | 1.2807 | 1.2807 | 2 | 0.0 | 1 |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
IRONWOOD PHARMACEUTICALS INC IRWD | 2023-11-28 22:15:04 UTC | 4.9031 | 0.4169 | 5200000 |
IRONWOOD PHARMACEUTICALS INC IRWD | 2023-11-28 21:45:03 UTC | 4.9031 | 0.4169 | 5200000 |
IRONWOOD PHARMACEUTICALS INC IRWD | 2023-11-28 21:15:04 UTC | 4.9031 | 0.4169 | 5200000 |
IRONWOOD PHARMACEUTICALS INC IRWD | 2023-11-28 20:45:04 UTC | 4.9031 | 0.4169 | 5200000 |
IRONWOOD PHARMACEUTICALS INC IRWD | 2023-11-28 20:15:04 UTC | 4.9031 | 0.4169 | 5200000 |
IRONWOOD PHARMACEUTICALS INC IRWD | 2023-11-28 19:45:03 UTC | 4.9031 | 0.4169 | 5200000 |
IRONWOOD PHARMACEUTICALS INC IRWD | 2023-11-28 19:15:04 UTC | 4.903 | 0.417 | 5200000 |
IRONWOOD PHARMACEUTICALS INC IRWD | 2023-11-28 18:45:03 UTC | 4.903 | 0.417 | 5200000 |
IRONWOOD PHARMACEUTICALS INC IRWD | 2023-11-28 18:15:03 UTC | 4.903 | 0.417 | 5200000 |
IRONWOOD PHARMACEUTICALS INC IRWD | 2023-11-28 17:45:04 UTC | 4.903 | 0.417 | 5200000 |
IRONWOOD PHARMACEUTICALS INC IRWD | 2023-11-28 17:15:04 UTC | 4.903 | 0.417 | 5200000 |
IRONWOOD PHARMACEUTICALS INC IRWD | 2023-11-28 16:45:04 UTC | 4.903 | 0.417 | 5200000 |
IRONWOOD PHARMACEUTICALS INC IRWD | 2023-11-28 16:15:04 UTC | 4.903 | 0.417 | 5200000 |
IRONWOOD PHARMACEUTICALS INC IRWD | 2023-11-28 15:45:03 UTC | 4.903 | 0.417 | 5200000 |
IRONWOOD PHARMACEUTICALS INC IRWD | 2023-11-28 15:15:03 UTC | 4.903 | 0.417 | 5200000 |
IRONWOOD PHARMACEUTICALS INC IRWD | 2023-11-28 14:45:04 UTC | 4.9014 | 0.4186 | 5200000 |
IRONWOOD PHARMACEUTICALS INC IRWD | 2023-11-28 14:15:04 UTC | 4.9014 | 0.4186 | 5200000 |
IRONWOOD PHARMACEUTICALS INC IRWD | 2023-11-28 13:45:04 UTC | 4.9014 | 0.4186 | 5200000 |
IRONWOOD PHARMACEUTICALS INC IRWD | 2023-11-28 13:15:03 UTC | 4.9014 | 0.4186 | 5200000 |
IRONWOOD PHARMACEUTICALS INC IRWD | 2023-11-28 12:45:04 UTC | 4.9014 | 0.4186 | 5200000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
FundVantage Trust- Gotham Index Plus All-Cap Fund | IRWD | -13.0 shares, $-131.17 | 2020-03-31 | N-PORT |
FORUM FUNDS- ABSOLUTE CONVERTIBLE ARBITRAGE FUND | IRWD | -211201.0 shares, $-2247178.64 | 2023-06-30 | N-PORT |
Calamos Investment Trust/IL- Calamos Market Neutral Income Fund | IRWD | -747630.0 shares, $-8291216.7 | 2023-07-31 | N-PORT |